CA1309655C - Traitement d'allergies par une immunotoxine - Google Patents

Traitement d'allergies par une immunotoxine

Info

Publication number: CA1309655C
Authority: CA; Canada
Prior art keywords: immunotoxin; ige; antibody; toxin; chain
Prior art date: 1987-10-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA000548626A

Other languages

English (en)

Inventor

Robert Blake Whitaker Jr.

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

IMMUNET

Original Assignee

IMMUNET

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-10-05

Filing date

1987-10-05

Publication date

1992-11-03

1987-10-05 Application filed by IMMUNET filed Critical IMMUNET

1987-10-05 Priority to CA000548626A priority Critical patent/CA1309655C/fr

1992-11-03 Application granted granted Critical

1992-11-03 Publication of CA1309655C publication Critical patent/CA1309655C/fr

2009-11-03 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

230000002637 immunotoxin Effects 0.000 title claims abstract description 69
229940051026 immunotoxin Drugs 0.000 title claims abstract description 69
239000002596 immunotoxin Substances 0.000 title claims abstract description 69
231100000608 immunotoxin Toxicity 0.000 title claims abstract description 69
206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 37
208000026935 allergic disease Diseases 0.000 title claims abstract description 31
230000007815 allergy Effects 0.000 title claims abstract description 25
238000002560 therapeutic procedure Methods 0.000 title description 9
239000003053 toxin Substances 0.000 claims description 21
231100000765 toxin Toxicity 0.000 claims description 21
230000000694 effects Effects 0.000 claims description 12
239000012634 fragment Substances 0.000 claims description 11
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 10
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 10
108700028325 pokeweed antiviral Proteins 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 4
238000005859 coupling reaction Methods 0.000 claims description 3
238000000101 transmission high energy electron diffraction Methods 0.000 claims 1
210000003719 b-lymphocyte Anatomy 0.000 abstract description 15
238000000034 method Methods 0.000 abstract description 8
210000004027 cell Anatomy 0.000 description 24
238000011282 treatment Methods 0.000 description 22
241000699670 Mus sp. Species 0.000 description 17
239000002953 phosphate buffered saline Substances 0.000 description 12
108060003951 Immunoglobulin Proteins 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
102000018358 immunoglobulin Human genes 0.000 description 9
229940092253 ovalbumin Drugs 0.000 description 9
239000013566 allergen Substances 0.000 description 8
210000000805 cytoplasm Anatomy 0.000 description 8
241000283707 Capra Species 0.000 description 7
241000282414 Homo sapiens Species 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
108010039491 Ricin Proteins 0.000 description 6
239000000427 antigen Substances 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
230000003053 immunization Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
238000013459 approach Methods 0.000 description 5
238000003556 assay Methods 0.000 description 5
XKSOTQXTPALQMY-UHFFFAOYSA-N 1-[3-[(4-azidophenyl)disulfanyl]propanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCSSC1=CC=C(N=[N+]=[N-])C=C1 XKSOTQXTPALQMY-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
108010058846 Ovalbumin Proteins 0.000 description 4
241000700159 Rattus Species 0.000 description 4
238000002649 immunization Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
208000003455 anaphylaxis Diseases 0.000 description 3
230000030833 cell death Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
230000009610 hypersensitivity Effects 0.000 description 3
231100000636 lethal dose Toxicity 0.000 description 3
238000012552 review Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
206010002198 Anaphylactic reaction Diseases 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
229940037003 alum Drugs 0.000 description 2
230000036783 anaphylactic response Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000000586 desensitisation Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
230000012202 endocytosis Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
241000894007 species Species 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
241001239379 Calophysus macropterus Species 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
108010017507 Ricinus communis agglutinin-1 Proteins 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229960003699 evans blue Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000007925 intracardiac injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000000207 lymphocyte subset Anatomy 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA000548626A 1987-10-05 1987-10-05 Traitement d'allergies par une immunotoxine Expired - Fee Related CA1309655C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000548626A CA1309655C (fr)	1987-10-05	1987-10-05	Traitement d'allergies par une immunotoxine

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000548626A CA1309655C (fr)	1987-10-05	1987-10-05	Traitement d'allergies par une immunotoxine

Publications (1)

Publication Number	Publication Date
CA1309655C true CA1309655C (fr)	1992-11-03

Family

ID=4136587

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000548626A Expired - Fee Related CA1309655C (fr)	1987-10-05	1987-10-05	Traitement d'allergies par une immunotoxine

Country Status (1)

Country	Link
CA (1)	CA1309655C (fr)

1987
- 1987-10-05 CA CA000548626A patent/CA1309655C/fr not_active Expired - Fee Related

Legal Events

Date	Code	Title	Description
2004-11-03	MKLA	Lapsed

Publication	Publication Date	Title
US4714759A (en)	1987-12-22	Immunotoxin therapy of allergy
US6258358B1 (en)	2001-07-10	Targeted immunostimulation with bispecific reagents
Golan et al.	1971	Nonantigenicity and immunologic tolerance: the role of the carrier in the induction of tolerance to the hapten
Ishizaka et al.	1984	through IgE Receptors
Snider et al.	1987	Targeted antigen presentation using crosslinked antibody heteroaggregates.
Grzych et al.	1984	Blocking activity of rat monoclonal antibodies in experimental schistosomiasis.
US5547668A (en)	1996-08-20	Conjugates of folate anti-effector cell antibodies
JPH021129B2 (fr)	1990-01-10
Hammer et al.	1971	Detection of homocytotropic antibody associated with a unique immunoglobulin class in the bovine species
CA2015515C (fr)	1999-12-07	Composes pharmaceutiques contenant des complexes antigene-anticorps et leur utilisation
Agodoa et al.	1983	Precipitating antigen-antibody systems are required for the formation of subepithelial electron-dense immune deposits in rat glomeruli.
Lees et al.	1990	Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody.
Hall et al.	1977	Passive transfer of autoimmune disease with isologous IgG1 and IgG2 antibodies to the tubular basement membrane in strain XIII guinea pigs: loss of self-tolerance induced by autoantibodies.
US4906469A (en)	1990-03-06	Appropriate cytotoxic pharmaceutical combination especially for the treatment of cancers
JPH01501793A (ja)	1989-06-22	透明帯に対する免疫化による避妊のための方法
CA1309655C (fr)	1992-11-03	Traitement d'allergies par une immunotoxine
KR920005691B1 (ko)	1992-07-13	안지오제닌(Angiogenin)에 대한 항체 : 면역제
Stracke et al.	1987	Characterization of monoclonal antibodies produced by immunization with partially purified IgE receptor complexes
JP2735196B2 (ja)	1998-04-02	アレルギーの免疫毒素治療
WO1991008773A1 (fr)	1991-06-27	Conjugues immunoglobuline-proteine tolerogene
Graziano et al.	1979	Involvement of host Fc receptors in antibody-mediated cutaneous basophil hypersensitivity reactions
US5358710A (en)	1994-10-25	Method for the suppression of an immune response
WO2001032207A1 (fr)	2001-05-10	Procede permettant d'appliquer une immunotherapie active/passive
US4689400A (en)	1987-08-25	Enhancement of specific antibody production with anti-IgD antibodies
Tiu et al.	1989	Monoclonal antibodies reacting with Schistosoma japonicum eggs and their target epitopes